A detailed history of Sigma Planning Corp transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Sigma Planning Corp holds 19,835 shares of SNDX stock, worth $450,056. This represents 0.02% of its overall portfolio holdings.

Number of Shares
19,835
Holding current value
$450,056
% of portfolio
0.02%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 01, 2024

BUY
$19.71 - $24.57 $390,947 - $487,345
19,835 New
19,835 $472,000
Q3 2023

Nov 06, 2023

SELL
$14.52 - $21.77 $145 - $217
-10 Reduced 0.05%
20,750 $301,000
Q2 2023

Aug 01, 2023

SELL
$19.35 - $22.31 $48,181 - $55,551
-2,490 Reduced 10.71%
20,760 $434,000
Q1 2023

May 05, 2023

SELL
$20.66 - $28.98 $55,575 - $77,956
-2,690 Reduced 10.37%
23,250 $491,000
Q4 2022

Jan 24, 2023

BUY
$20.64 - $26.24 $6,192 - $7,871
300 Added 1.17%
25,940 $0
Q3 2022

Nov 10, 2022

BUY
$18.51 - $24.79 $33,318 - $44,622
1,800 Added 7.55%
25,640 $616,000
Q2 2022

Aug 11, 2022

SELL
$13.64 - $19.48 $10,230 - $14,610
-750 Reduced 3.05%
23,840 $459,000
Q4 2021

Feb 02, 2022

SELL
$15.23 - $22.47 $3,046 - $4,494
-200 Reduced 0.81%
24,590 $538,000
Q3 2021

Oct 28, 2021

SELL
$13.87 - $19.8 $6,241 - $8,910
-450 Reduced 1.78%
24,790 $474,000
Q2 2021

Aug 13, 2021

SELL
$13.42 - $25.18 $2,684 - $5,036
-200 Reduced 0.79%
25,240 $433,000
Q1 2021

May 06, 2021

SELL
$19.28 - $24.59 $1,638 - $2,090
-85 Reduced 0.33%
25,440 $569,000
Q4 2020

Feb 09, 2021

SELL
$15.1 - $26.44 $9,060 - $15,864
-600 Reduced 2.3%
25,525 $568,000
Q3 2020

Nov 03, 2020

BUY
$13.39 - $17.48 $1,339 - $1,748
100 Added 0.38%
26,125 $386,000
Q2 2020

Jul 31, 2020

BUY
$8.94 - $20.98 $232,663 - $546,004
26,025 New
26,025 $386,000
Q3 2019

Nov 01, 2019

SELL
$7.47 - $10.76 $91,731 - $132,132
-12,280 Closed
0 $0
Q2 2019

Aug 01, 2019

BUY
$4.9 - $9.31 $60,172 - $114,326
12,280 New
12,280 $114,000

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $1.28B
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Sigma Planning Corp Portfolio

Follow Sigma Planning Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

News

Stay updated on Sigma Planning Corp with notifications on news.